Study in Patients With Asthma
This study has been completed.
Information provided by:
First received: September 13, 2005
Last updated: November 10, 2010
Last verified: February 2008
The purpose of this study is to determine which dose of the investigational drug is the most safe and effective in the treatment of asthma compared to the control drug.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Primary Purpose: Treatment
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Dey:
Primary Outcome Measures:
- The primary outcome variable is the measure of lung function.
Secondary Outcome Measures:
- Secondary outcomes include change in lung function, as well as in vital signs.
- Physical exams, AE reporting, etc.
|Study Completion Date:||December 2005|
|Primary Completion Date:||February 2003 (Final data collection date for primary outcome measure)|
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00215397
|United States, California|
|Long Beach, California, United States, 90806|
|United States, Colorado|
|Denver, Colorado, United States, 80206|
|United States, Oregon|
|Medford, Oregon, United States, 97504|
Sponsors and Collaborators